Prednisolone

• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Ended
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and … Ended
  2024-516403-16-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended
  2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended
  2022-500237-92-00 Phase III 11 countries Incyte Corp.
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended
  2024-511637-35-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended
  2023-505830-89-00 Phase IV 10 countries Bayer AG; Bayer Consumer Care AG
• Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended
  2024-516102-36-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended
  2024-515953-52-00 Phase III 8 countries Sobi Inc.
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended
  2023-503628-22-00 Phase III 5 countries F. Hoffmann-La Roche AG
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended
  2023-510248-19-00 Phase III 4 countries AstraZeneca AB
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended
  2023-504821-38-00 Phase II 8 countries Merck Sharp & Dohme LLC
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended
  2024-511641-18-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended
  2022-501038-48-00 Phase II 2 countries Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended
  2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended
  2024-512470-10-00 Phase III/IV 1 country Centre Hospitalier Departemental Vendee
• ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended
  2024-514275-18-00 Phase II/III 4 countries Region Skane; University Hospitals Plymouth NHS Trust
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended
  2023-510298-33-00 Phase II 15 countries Astellas Pharma Global Development Inc.
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended
  2024-515846-18-00 Phase I (FiH) 2 countries LYSARC
• HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended
  2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands

Showing 73–96 of 119 trials